middl
east
respiratori
syndrom
coronaviru
merscov
caus
spectrum
ill
evalu
whether
cycl
threshold
c
valu
invers
relat
viru
load
associ
clinic
sever
patient
saudi
arabia
whose
nasopharyng
specimen
test
posit
viru
realtim
revers
transcript
pcr
among
patient
median
c
upstream
e
gene
target
patient
die
significantli
lower
median
survivor
p
multivari
regress
analys
risk
factor
death
age
year
underli
ill
decreas
c
result
similar
composit
sever
outcom
death
andor
intens
care
unit
admiss
data
need
determin
whether
modul
viru
load
therapeut
agent
affect
clinic
outcom
cov
first
report
septemb
patient
kingdom
saudi
arabian
ksa
pneumonia
septemb
januari
total
merscov
case
fatal
report
ksa
repres
case
worldwid
initi
report
clinic
cours
among
merscov
patient
ksa
indic
high
casefat
rate
subsequ
increas
test
symptomat
asymptomat
person
part
contact
investig
shown
approxim
one
fifth
one
fourth
patient
mildli
symptomat
asymptomat
factor
dictat
sever
ill
outcom
among
merscov
patient
still
well
defin
underli
ill
older
age
associ
sever
diseas
death
viral
respiratori
ill
amount
viru
measur
respiratori
tract
associ
sever
diseas
howev
whether
viru
load
merscov
associ
sever
ill
unknown
evalu
associ
among
larg
cohort
merscov
patient
jeddah
region
ksa
elig
person
children
adult
admit
jeddah
area
hospit
marchmay
patient
includ
met
follow
criteria
test
posit
merscov
realtim
revers
transcript
pcr
rtpcr
nasopharyng
swab
sputum
bronchoalveolar
lavag
sampl
jeddah
region
laboratori
march
match
line
list
jeddah
merscov
patient
complet
clinic
outcom
data
data
collect
jeddah
region
laboratori
maintain
databas
patient
test
includ
cycl
threshold
c
valu
upstream
envelop
e
upe
gene
open
read
frame
orf
target
composit
merscov
patient
medic
histori
clinic
inform
obtain
case
report
form
medic
record
review
phone
call
compil
late
may
laboratori
clinic
dataset
link
match
nation
identif
number
saudi
foreign
identif
number
foreign
number
close
exact
match
confirmatori
evid
ident
includ
sex
age
date
specimen
collect
person
identifi
includ
identif
number
strip
merg
analyt
dataset
patient
suspect
merscov
infect
test
soon
possibl
admiss
jeddah
area
hospit
discret
treat
clinician
guidanc
ksa
ministri
health
moh
addit
close
contact
confirm
merscov
patient
health
care
worker
care
merscov
patient
sampl
part
contact
investig
ksa
moh
guidelin
recommend
collect
nasopharyng
swab
screen
specimen
patient
suspect
merscov
enabl
addit
collect
lower
respiratori
tract
specimen
intub
patient
swab
sampl
obtain
use
dacron
flock
swab
place
ml
viru
transport
media
specimen
store
transport
jeddah
region
laboratori
within
hour
collect
jeddah
region
laboratori
total
nucleic
acid
extract
clinic
specimen
perform
use
magna
pure
lc
magna
pure
compact
roch
basel
switzerland
instrument
program
protocol
roch
sampl
volum
elut
volum
realtim
rtpcr
amplif
perform
use
modulardx
coronaviru
emc
upstream
egen
kit
tib
molbiol
llc
berlin
germani
primari
detect
modulardx
merscoronaviru
emc
kit
tib
molbiol
llc
use
confirm
posit
result
discord
result
need
confirm
second
clinic
specimen
c
valu
read
posit
amplif
curv
cross
threshold
set
background
fluoresc
level
standard
curv
gener
realtim
rtpcr
run
absolut
viru
concentr
specimen
calcul
upe
c
valu
highli
correl
spearman
upe
region
noncod
would
less
influenc
presenc
mrna
primari
analys
run
upe
c
valu
main
outcom
interest
studi
sever
ill
main
predictor
assess
merscov
viru
load
reflect
c
valu
follow
sever
outcom
assess
death
time
followup
chart
review
phone
contact
composit
sever
outcom
death
andor
admiss
intens
care
unit
icu
admiss
icu
versu
admiss
gener
ward
among
hospit
patient
symptomat
versu
asymptomat
infect
among
surviv
patient
independ
variabl
analysi
risk
factor
andor
potenti
confound
associ
c
valu
outcom
underli
ill
age
sex
week
specimen
collect
c
valu
use
rel
indic
viru
load
lower
c
valu
consid
reflect
higher
viru
load
higher
c
valu
intrins
characterist
realtim
rtpcr
analysi
associ
c
valu
sever
restrict
nasopharyng
specimen
c
valu
lower
respiratori
tract
specimen
eg
sputum
bronchoalveolar
lavag
lower
ie
higher
viru
load
upper
respiratori
tract
specimen
therebi
introduc
possibl
bia
evalu
sever
multipl
specimen
avail
patient
nasopharyng
sampl
earliest
date
collect
use
underli
ill
defin
heart
diseas
chronic
lung
diseas
renal
diseas
andor
diabet
age
divid
quartil
base
age
distribut
merscovposit
patient
assess
whether
chang
might
occur
time
period
test
confound
result
eg
specimen
collect
transport
method
creat
categor
variabl
base
date
specimen
collect
period
march
day
sinc
ill
onset
differ
date
first
symptom
mer
ie
cough
dyspnea
fever
date
specimen
collect
c
distribut
normal
distribut
compar
c
valu
group
use
wilcoxon
rank
sum
test
group
use
kruskalw
test
c
valu
also
group
high
viru
load
c
medium
viru
load
c
low
viru
load
c
valu
categor
analysi
group
compar
use
test
brett
whittak
per
comm
group
c
valu
correl
continu
variabl
c
valu
compar
valu
rank
assess
spearman
rank
correl
coeffici
spearman
univari
multivari
logist
regress
perform
identifi
risk
factor
death
well
composit
sever
outcom
death
andor
icu
admiss
among
merscovposit
patient
categor
variabl
miss
data
code
includ
miss
valid
respons
categori
variabl
p
univari
analysi
includ
multivari
analys
backward
forward
select
method
perform
identifi
signific
variabl
p
categori
variabl
main
focu
determin
whether
outcom
interest
ie
death
composit
sever
outcom
like
c
valu
decreas
ie
viru
load
increas
variabl
consid
signific
confound
c
associ
paramet
estim
c
chang
includ
model
regardless
statist
signific
separ
analys
run
c
valu
result
upe
rtpcr
target
analys
perform
use
sa
sa
institut
cari
nc
usa
formal
sampl
size
calcul
rather
elig
patient
studi
period
includ
analysi
studi
period
clinic
laboratori
dataset
merscovposit
patient
abl
link
seventythre
percent
men
median
age
patient
year
rang
year
patient
inform
age
miss
thirtytwo
patient
health
care
worker
saudi
specimen
merscov
collect
facil
specimen
collect
facil
remain
facil
provid
sampl
addit
specimen
collect
home
asymptomat
mildli
symptomat
contact
mean
median
c
valu
link
merscovposit
patient
upe
respect
rang
patient
result
avail
mean
median
c
valu
respect
rang
correl
upe
c
valu
high
r
p
spearman
median
c
upe
target
nasopharyng
swab
sampl
sputum
sampl
bronchoalveolar
lavag
sampl
p
kruskalw
test
figur
restrict
hospit
patient
median
c
valu
nasopharyng
swab
sputum
bronchoalveolar
lavag
sampl
respect
p
kruskalw
test
remain
analysi
restrict
patient
nasopharyng
swab
sampl
known
outcom
statu
patient
die
c
valu
upe
target
patient
die
significantli
lower
patient
surviv
median
respect
p
wilcoxon
rank
sum
test
figur
panel
use
composit
sever
variabl
categor
ill
sever
patient
ct
valu
significantli
lower
patient
without
sever
diseas
median
respect
p
wilcoxon
rank
sum
test
figur
panel
b
sixtyseven
patient
hospit
c
valu
significantli
lower
hospit
patient
admit
icu
hospit
patient
admit
gener
ward
median
respect
p
wilcoxon
rank
sum
test
figur
panel
c
patient
surviv
ct
valu
significantli
lower
symptomat
patient
mildli
symptomat
asymptomat
patient
median
respect
p
wilcoxon
rank
sum
test
figur
panel
found
similar
associ
categor
c
valu
low
medium
high
tabl
find
similar
data
shown
age
associ
c
assess
either
continu
variabl
r
p
spearman
quartil
p
kruskalw
test
patient
inform
avail
day
ill
onset
swab
sampl
collect
found
correl
day
sinc
onset
c
continu
variabl
r
p
spearman
figur
higher
viru
load
found
earlier
cours
ill
among
patient
presenc
patient
absenc
patient
underli
ill
note
c
valu
differ
significantli
median
respect
p
wilcoxon
rank
sum
test
surviv
hospit
patient
enough
inform
avail
calcul
length
hospit
stay
median
day
c
length
stay
correl
patient
r
p
spearman
c
valu
differ
significantli
hospit
sampl
collect
p
kruskalw
test
univari
logist
regress
increas
probabl
death
predict
older
age
presenc
underli
ill
lower
c
tabl
multivari
analysi
year
age
odd
ratio
ci
underli
ill
ci
strongest
predictor
death
lower
c
valu
remain
predict
death
adjust
age
presenc
underli
ill
odd
death
increas
point
drop
c
ci
composit
sever
outcom
factor
identifi
univari
multivari
analysi
c
borderlin
signific
ci
adjust
age
underli
ill
tabl
found
similar
regress
result
adjust
underli
ill
age
posit
associ
lower
c
valu
death
ci
sever
diseas
ci
found
associ
higher
viru
load
merscov
detect
upper
respiratori
tract
indic
lower
c
valu
wors
clinic
outcom
includ
death
admiss
icu
find
deriv
larg
number
merscov
patient
ksa
upsurg
case
spring
merscov
diagnos
patient
spectrum
clinic
ill
find
chang
adjust
risk
factor
sever
outcom
potenti
confound
although
exact
pathophysiolog
merscov
infect
lung
still
unknown
virion
could
lead
wors
lung
damag
either
direct
destruct
respiratori
epitheli
cell
trigger
vigor
inflammatori
respons
sever
acut
respiratori
syndrom
coronaviru
infect
similar
associ
observ
wors
outcom
higher
viru
load
measur
nasopharyng
serum
fecal
sampl
patient
higher
merscov
viru
load
unclear
viru
load
might
relat
inoculum
size
time
infect
anecdot
primari
merscov
infect
probabl
like
acquir
environment
exposur
eg
camel
persontoperson
spread
tend
wors
outcom
even
among
younger
patient
although
factor
could
reflect
risk
case
ascertain
bia
viru
load
might
also
relat
host
factor
immun
respons
viru
turn
could
affect
intrins
factor
presenc
underli
ill
host
genet
associ
outcom
viru
load
upper
respiratori
tract
demonstr
previous
viral
infect
children
higher
respiratori
syncyti
viru
load
like
hospit
requir
mechan
ventil
studi
found
higher
viru
load
influenza
virus
among
patient
sicker
higher
viru
load
human
bocaviru
nasopharyng
aspir
sampl
associ
greater
sever
ill
among
chines
children
studi
howev
shown
associ
viru
load
ill
sever
clearli
specimen
type
affect
viru
load
previou
studi
ksa
show
median
c
valu
lower
merscov
tracheal
aspir
bronchoaveolar
lavag
sampl
nasopharyng
swab
sampl
presum
reflect
higher
viru
load
lower
respiratori
tract
moreov
lower
respiratori
tract
sampl
includ
expector
sputum
posit
merscov
upper
respiratori
tract
sampl
neg
observ
similar
find
bronchoalveolar
lavag
sputum
yield
higher
viru
load
nasopharyng
specimen
although
could
reflect
specimen
avail
sicker
patient
due
chanc
bronchoalveolar
sputum
specimen
sever
patient
like
associ
avail
specimen
eg
intub
patient
bronchoalveolar
lavag
restrict
analysi
patient
nasopharyng
swab
sampl
recommend
specimen
initi
merscov
diagnosi
accord
ksa
moh
guidelin
clinic
implic
measur
viru
load
upper
respiratori
tract
specimen
merscov
clear
viru
load
probabl
reflect
viru
replic
nasopharyng
epitheli
cell
assum
viru
load
upper
respiratori
tract
correl
lung
although
assumpt
known
definit
limit
analysi
viru
load
among
bronchoalveolar
lavag
specimen
would
abl
directli
compar
viru
load
lung
clinic
sever
howev
specimen
avail
conduct
analysi
show
sever
risk
factor
associ
death
sever
outcom
multivari
analysi
strongest
risk
factor
elderli
underli
ill
although
sever
studi
shown
underli
ill
common
among
merscov
patient
includ
die
quantifi
risk
underli
ill
sever
outcom
show
presenc
underli
ill
elev
odd
sever
outcom
death
higher
risk
sever
outcom
earlier
cours
jeddah
outbreak
probabl
due
increas
contact
trace
outbreak
progress
jeddah
lead
detect
greater
spectrum
clinic
merscov
diseas
later
outbreak
analysi
subject
sever
possibl
limit
c
valu
semiquantit
measur
viru
load
therefor
reflect
rel
viru
load
without
refer
known
standard
curv
realtim
rtpcr
run
abl
assign
specif
viru
load
threshold
sever
categori
runtorun
variabl
could
exist
c
viru
load
relationship
although
extract
method
realtim
rtpcr
equip
remain
throughout
period
jeddah
region
laboratori
realtim
rtpcr
effici
chang
c
indic
differ
concentr
viru
copi
although
condit
rare
met
realworld
practic
c
valu
use
report
indic
merscov
viru
load
second
specimen
collect
multipl
hospit
home
set
asymptomat
contact
could
led
variabl
qualiti
specimen
andor
handl
ship
practic
get
specimen
jeddah
region
laboratori
howev
unless
systemat
differ
present
site
term
sever
ill
affect
specimen
collect
variabl
nondifferenti
bias
find
toward
null
moreov
observ
differ
median
c
across
hospit
third
data
outcom
indic
sever
ill
either
miss
patient
eg
day
sinc
onset
length
hospit
stay
avail
current
dataset
eg
mechan
ventil
oxygen
requir
fourth
patient
initi
identifi
moh
asymptomat
hospit
medic
record
review
data
collect
phone
patient
patient
unabl
contact
could
verifi
initi
data
moh
lead
potenti
misclassif
variabl
final
without
systemat
sampl
test
sequenti
specimen
patient
cours
ill
unabl
determin
tempor
sequenc
associ
viru
load
outcom
ie
determin
whether
higher
viru
load
causal
lead
sever
outcom
although
present
evid
epidemiolog
associ
viru
load
sever
merscov
ill
clinic
implic
find
unclear
time
merscov
known
treatment
support
care
sever
approach
treatment
includ
antivir
drug
immunotherapi
investig
data
need
whether
modul
viru
load
therapeut
agent
affect
clinic
outcom
